Barclays’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Barclays’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-177	Closed	-$14K	–	4940
2021 Q2	$14K	Buy	+177	New	+$14.1K	﹤0.01%	4569

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Barclays's PJP Position: Q3 2021 in Review

Barclays sold out of Invesco Pharmaceuticals ETF (PJP) in Q3 2021, closing a stake of 177 shares — an estimated $14K sold.

Barclays first reported a position in PJP in Q2 2021 and held it in 1 quarter. The position peaked at $14K in Q2 2021. 94 funds tracked by Wall St. Rank hold PJP as of Q3 2021.

Barclays reported no remaining Invesco Pharmaceuticals ETF position as of Q3 2021 after selling out during the quarter.
Barclays sold 177 Invesco Pharmaceuticals ETF shares in Q3 2021, an estimated $14K.
Barclays first reported a position in Invesco Pharmaceuticals ETF in Q2 2021 and held it in 1 quarter.
Barclays's Invesco Pharmaceuticals ETF position peaked at $14K in Q2 2021.
94 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.